Table 2.
Clinical trials using nanomaterials for several applications.
| Nanoparticle | Application | Identifier |
|---|---|---|
| Hafnium oxide (HfO2) nanoparticle activated by radiotherapy | Locoregional recurrent (LRR) or recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) and lung and liver metastases from any primary cancer eligible for anti-PD-1 therapy | NCT03589339 |
| Iron NPs. Magnetic responsive for Thermo-ablation | Prostate Cancer | NCT02033447 |
| Superparamagnetic iron oxide nanoparticles (SPIONs) with spinning magnetic field | Osteosarcoma | NCT04316091 |
| Magnetic nanoparticles with cultured human corneal endothelial cells | Corneal edema | NCT04894110 |
| Carbon nanoparticles | Lymph node tracer in rectal cancer |
NCT03550001 NCT04482803 NCT04759820 |
| Liposomes containing RNA for patient-specific tumor-associated antigens and p53 RNA | Triple-negative breast cancer | NCT02316457 |
| Nab-paclitaxel pegylated liposomal doxorubicin (PLD) | Triple-negative breast cancer or ovarian cancer | NCT03719326 |
| Lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ | Relapsed/refractory solid tumor malignancies or lymphoma | NCT03739931 |
| Nab-paclitaxel/rituximab-coated nanoparticle AR160 | Non-Hodgkin lymphoma | NCT03003546 |
| Nab-paclitaxel-pegylated liposomal doxorubicin hydrochloride l | Advanced solid tumors (spread to other places in the body) | NCT03907475 |
| Lipid nanoparticle carrying mRNA | COVID-19 vaccine |
NCT04813796 NCT04860258 NCT04838847 NCT04674189 NCT04652102 NCT04515147 NCT04449276 NCT04848467 |
| Lipid nanoparticle carrying mRNA | Respiratory syncytial virus vaccine | NCT04528719 |
| Lipid nanoparticle carrying mRNA | Rabies vaccine | NCT03713086 |
| Lipid nanoparticle carrying mRNA | Cytomegalovirus vaccine | NCT04232280 |
| Lipid nanoparticle carrying mRNA | Combined human metapneumovirus and parainfluenza virus type 3 vaccine | NCT04144348 |
| Lipid nanoparticle carrying mRNA | Advanced solid tumor malignancies | NCT03323398 |
| Lipid nanoparticle carrying mRNA | Advanced solid tumor malignancies |
NCT03739931 NCT02872025 |
| Lipid nanoparticle carrying mRNA | Personalized cancer vaccine |
NCT03313778 NCT03897881 |
| Lipid nanoparticle carrying mRNA | KRAS vaccine | NCT03948763 |
| Lipid nanoparticle carrying mRNA | Personalized cancer vaccine |
NCT03313778 NCT03897881 |
| Lipid nanoparticle carrying mRNA | Advanced solid tumors | NCT03946800 |
| Lipid nanoparticle carrying mRNA | COVID-19 vaccine | NCT04821674 |
| Size- and charge-based RNA-lipoplex nanoparticles for targeting dendritic cells | Metastatic melanoma vaccine | NCT04526899 |
| Size- and charge-based RNA-lipoplex nanoparticles for targeting dendritic cells | Prostate cancer vaccine | NCT04382898 |
| Size- and charge-based RNA-lipoplex nanoparticles for targeting dendritic cells | Head and neck cancer vaccine | NCT04534205 |
| mRNA-lipoplex nanoparticles | Ovarian cancer | NCT04163094 |
| Size- and charge-based RNA-lipoplex nanoparticles for targeting dendritic cells | Colorectal cancer, melanoma, lung cancer, bladder cancer |
NCT04486378 NCT03815058 NCT03289962 |
| Liver-targeting lipid nanoparticle | Multiple solid tumors |
NCT04710043 NCT04455620 NCT04710043 |
| Size- and charge-based RNA-lipoplex nanoparticles for targeting dendritic cells | Solid tumor | NCT04503278 |
| Lipid-enabled and unlocked nucleomonomer agent mRNA (LUNAR®®) | COVID-19 vaccine |
NCT04728347 NCT04668339 NCT04480957 |
| Lipid-enabled and unlocked nucleomonomer agent mRNA (LUNAR®®) | Ornithine transcarbamylase deficiency | NCT04442347 |
| Liposome | Advanced lymphoid malignancies | NCT04072458 |
| Army liposomal formulation (adjuvant) | COVID-19 vaccine | NCT04784767 |
| Lipid-Inorganic Nanoparticle (LION™); 15-nm superparamagnetic iron oxide | COVID-19 vaccine (repRNA) | NCT04844268 |
| Lipid nanoparticles | Transthyretin amyloidosis | NCT04601051 |
| Large surface area microparticles (nanoparticulates) | Urothelial carcinoma |
NCT03636256 NCT04060628 |
| Large surface area microparticles (nanoparticulates) | Pancreatic adenocarcinoma, lung cancer |
NCT04314895 NCT03077685 NCT03756311 |
| Poly(lactic-co-glycolic acid) (PLGA) nanoparticle | Esophageal Squamous Cell Carcinoma-1 positive cancers | NCT04751786 |
| Self-assembling protein nanoparticle immunogens | COVID-19 vaccine |
NCT04742738 NCT04750343 |
| Recombinant hemagglutinin protein nanoparticle with saponin-based Matrix-M adjuvant | Influenza vaccine | NCT04120194 |
| Recombinant spike protein nanoparticle with saponin-based Matrix-M1 adjuvant | COVID-19 vaccine |
NCT04611802 NCT04368988 NCT04533399 NCT04583995 |